141 related articles for article (PubMed ID: 29907230)
1. A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.
Williams AP; Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
J Surg Res; 2018 Aug; 228():54-62. PubMed ID: 29907230
[TBL] [Abstract][Full Text] [Related]
2. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2015 Jul; 14(7):1559-69. PubMed ID: 25944918
[TBL] [Abstract][Full Text] [Related]
4. UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
Garner EF; Stafman LL; Williams AP; Aye JM; Goolsby C; Atigadda VR; Moore BP; Nan L; Stewart JE; Hjelmeland AB; Friedman GK; Beierle EA
J Neurooncol; 2018 Nov; 140(2):209-224. PubMed ID: 30132166
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2016 May; 15(5):911-21. PubMed ID: 26873726
[TBL] [Abstract][Full Text] [Related]
6. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).
Vedell PT; Lu Y; Grubbs CJ; Yin Y; Jiang H; Bland KI; Muccio DD; Cvetkovic D; You M; Lubet R
Mol Pharmacol; 2013 Mar; 83(3):698-708. PubMed ID: 23292798
[TBL] [Abstract][Full Text] [Related]
7. Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis.
Wu L; Chaudhary SC; Atigadda VR; Belyaeva OV; Harville SR; Elmets CA; Muccio DD; Athar M; Kedishvili NY
PLoS One; 2016; 11(4):e0153556. PubMed ID: 27078158
[TBL] [Abstract][Full Text] [Related]
8. Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.
Kim MS; Lim DY; Kim JE; Chen H; Lubet RA; Dong Z; Bode AM
Mol Carcinog; 2015 Dec; 54(12):1596-604. PubMed ID: 25328014
[TBL] [Abstract][Full Text] [Related]
9. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
10. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.
Jiang W; Deng W; Bailey SK; Nail CD; Frost AR; Brouillette WJ; Muccio DD; Grubbs CJ; Ruppert JM; Lobo-Ruppert SM
Cancer Biol Ther; 2009 Feb; 8(3):289-98. PubMed ID: 19197145
[TBL] [Abstract][Full Text] [Related]
11. Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma.
Marayati R; Williams AP; Bownes LV; Quinn CH; Stewart JE; Mroczek-Musulman E; Atigadda VR; Beierle EA
J Pediatr Surg; 2020 Jun; 55(6):1072-1080. PubMed ID: 32164984
[TBL] [Abstract][Full Text] [Related]
12. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention.
Kapetanovic IM; Horn TL; Johnson WD; Cwik MJ; Detrisac CJ; McCormick DL
Int J Toxicol; 2010; 29(2):157-64. PubMed ID: 20335511
[TBL] [Abstract][Full Text] [Related]
13. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
15. Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity.
Ricaud S; Vernus B; Bonnieu A
Exp Cell Res; 2005 Dec; 311(2):192-204. PubMed ID: 16236281
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
17. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
Muccio DD; Brouillette WJ; Breitman TR; Taimi M; Emanuel PD; Zhang X; Chen G; Sani BP; Venepally P; Reddy L; Alam M; Simpson-Herren L; Hill DL
J Med Chem; 1998 May; 41(10):1679-87. PubMed ID: 9572893
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
[TBL] [Abstract][Full Text] [Related]
19. The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells.
Hansen NJ; Wylie RC; Phipps SM; Love WK; Andrews LG; Tollefsbol TO
Int J Oncol; 2007 Mar; 30(3):641-50. PubMed ID: 17273765
[TBL] [Abstract][Full Text] [Related]
20. Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.
Muccio DD; Atigadda VR; Brouillette WJ; Bland KI; Krontiras H; Grubbs CJ
Curr Top Med Chem; 2017; 17(6):676-695. PubMed ID: 27320329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
